Hos­pi­tals urged to par­take in COVID-19 stud­ies

Arab News - - News Saudi Arabia - SPA Riyadh

The King Ab­dul­lah In­ter­na­tional Med­i­cal Re­search Cen­ter (KAIMRC) has urged all Saudi hos­pi­tals to take part in clin­i­cal stud­ies ac­cred­ited by the

Saudi Food and Drug Author­ity to find treat­ments for COVID-19. KAIMRC is con­duct­ing clin­i­cal stud­ies to find treat­ments by us­ing dif­fer­ent anti-vi­ral drugs. The first study is test­ing the drug favipi­ravir, de­vel­oped in Ja­pan and used in mild cases.

The sec­ond study is be­ing con­ducted in co­op­er­a­tion with the Health Min­istry to test a com­bi­na­tion of two drugs, favipi­ravir and hy­drox­y­chloro­quine (an an­ti­malar­ial drug), with spe­cific doses, to be adopted in mod­er­ate to se­vere cases.

The third study, con­ducted under the min­istry’s pa­tron­age, aims to test the pos­si­bil­ity of ex­tract­ing blood plasma from peo­ple who have re­cov­ered from COVID-19 to treat crit­i­cal cases where patients need ven­ti­la­tors or oxy­gen masks.

The fourth study is be­ing con­ducted to com­pare treat­ment pro­to­cols used for sev­eral groups to iden­tify the best one.

Dr. Ahmed Al-Askar, ex­ec­u­tive di­rec­tor of KAIMRC, said hos­pi­tals’ par­tic­i­pa­tion in these stud­ies is nec­es­sary to trace the ef­fects and re­sults of the drugs on patients and com­pare them with peo­ple who have not re­ceived the ex­per­i­men­tal treat­ments.

Newspapers in English

Newspapers from Saudi Arabia

© PressReader. All rights reserved.